![SENTRY study – investigating the safety and efficacy of the combination of selinexor plus ruxolitinib in myelofibrosis](https://oncodaily.com/pub/uploads/2024/08/GUtLWIVW8AEVCf3-e1723474696621.jpg)
Photo from Icahn School of Medicine at Mount Sinai/X
Aug 12, 2024, 13:49
SENTRY study – investigating the safety and efficacy of the combination of selinexor plus ruxolitinib in myelofibrosis
Icahn School of Medicine at Mount Sinai shared on X:
“The SENTRY study, led by Dr. John Mascarenhas, is investigating the safety and efficacy of the combination of selinexor (Xpovio) plus ruxolitinib (Jakafi) for the treatment of patients with JAK inhibitor treatment-naive myelofibrosis.”
Read further.
Source: Icahn School of Medicine at Mount Sinai/X